Basha et al. demonstrated that tolfenamic acid inhibits ovarian cancer (OC) cell growth in vitro and in vivo by disrupting Sp1-mediated regulation of c-Met, and they suggested that targeting c-Met by Sp1 protein degradation may be a promising strategy for OC therapeutic applications (30). This evidence concerns the gene SP1 and ovarian carcinoma.